[182 Pages Report] The Biobanking Market size was estimated at USD 70.33 billion in 2023 and expected to reach USD 78.21 billion in 2024, at a CAGR 11.71% to reach USD 152.75 billion by 2030.

Biobanking involves the collection, storage, management, processing, and distribution of biological samples from humans and animals for research and clinical purposes. It serves various sectors, including pharmaceuticals, biotechnology companies, academic institutions, and healthcare organizations. Applications include drug discovery, diagnostics development, personalized medicine research, and biomarker identification. Rising chronic disease prevalence such as cancer requires early detection and treatment methodologies and necessitates efficient sample storage, increasing deployment of biobanking. Moreover, increasing focus on precision medicine and government investments in national biobank networks are propelling the growth of the market. Furthermore, ensuring sample quality control and maintaining standardized protocols in collecting, processing, and storing samples are major concerns, as inconsistencies can lead to unreliable research outcomes. Data privacy is another pressing issue, with an increasing number of biobanks handling sensitive patient information. Also, leveraging emerging technologies including robotics automation systems for sample handling, enhancing data security through digitalization using blockchain technology, and implementing environmentally sustainable practices including energy-efficient storage units create lucrative opportunities for market growth.

In the Americas, the US biobanking industry plays a pivotal role in advancing biomedical research through initiatives such as the National Institutes of Health's All of Us Research Program. Furthermore, investments from state governments are driving the establishment of new biobanks. The EU biobanking market is bolstered by collaborations among various countries under initiatives such as Biobanking and BioMolecular resources Research Infrastructure-European Research Infrastructure Consortium (BBMRI-ERIC). Additionally, funding programs, including Horizon 2020, have facilitated advancements in personalized medicine. In Africa, initiatives including H3Africa have promoted the development of biorepositories across the continent to support genomics research on African populations. The APAC region is experiencing rapid growth due to government policies that allocate funds for medical innovation and precision medicine. India hosts several regional biobanks focusing on disease-specific applications such as cancer research.

The market dynamics represent an ever-changing landscape of the Biobanking Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

• Market Drivers
  • Increasing burden of chronic diseases across economies and need for better healthcare infrastructure
  • Growing private and public investments in pharmaceutical research
  • Rising awareness and government initiatives in regenerative medicine
• Market Restraints
  • Problems associated with procedure harmonization due to decentralized nature of biobanks
• Market Opportunities
  • Ongoing research to improve and ensure standardization of data acquisition and analysis in biobanks
  • Emerging focus on biobank sustainability and development of imaging biobanks
• Market Challenges
  • Ethical and legal concerns associated with biobanking

• Product: Expanding software integration to facilitate the biobanking operations

  Consumables in the biobanking sector are essential for maintaining biological samples' quality and integrity. These include sample collection kits, cryoboxes, cryovials, and barcode labels. The need-based preference for consumables is driven by factors such as product quality, reliability, and affordability. Equipment and instruments in biobanking encompass devices such as freezers, refrigerators, liquid nitrogen tanks, centrifuges, automated sample handling systems, and temperature monitoring devices. The need-based preference for equipment is determined by factors including energy efficiency, ease of use, automation capabilities, scalability, and compliance with industry standards. Biobank services consist of various support offerings ranging from sample collection management to cold chain logistics to data management services. Need-based preferences for service selection involve factors such as expertise in handling specific types of samples, regulatory compliance, and data security. Software solutions for biobanks facilitate the tracking, management, and analysis of biological samples and their associated data. Need-based preferences for software selection revolve around user-friendly interfaces, scalability, integration capabilities with existing systems, and robust security features.

• Sample Type: Increasing use of nucleic acid sample for genetic study

  Biological fluids encompass various body liquids including saliva, urine, cerebrospinal fluid (CSF), amniotic fluid, and synovial fluid. These samples are vital for investigating diseases' molecular signatures and identifying biomarkers. Blood products comprise whole blood, serum, plasma, buffy coat, red blood cells (RBCs), white blood cells (WBCs), and platelets. These samples are crucial in studying hematological disorders and immunological responses to external stimuli. Cell lines direct to a population of cells derived from a single organism and tissue source that can proliferate indefinitely under laboratory conditions. Cell lines serve as essential tools in cancer research and drug discovery processes due to their ease of manipulation and reproducibility across experiments. Human tissues comprise both healthy and diseased specimens obtained through surgical procedures, biopsies, or post-mortem donations. These samples are employed in studying tissue-specific gene expression patterns and identifying novel therapeutic targets for various diseases. Nucleic acids refer to DNA and RNA molecules extracted from biological samples such as blood, tissue, or cells. These macromolecules form the basis of genetic research, including disease-causing mutation identification, gene expression regulation studies, and molecular diagnostics applications.

• Storage Type: Rising preference for automated storage systems due to its efficiency and scalability

  Automated storage systems have gained popularity owing to their efficiency, accuracy, and reduced risk of contamination. These systems utilize robotics and advanced technologies to manage sample storage and retrieval processes without requiring manual intervention. Manual storage systems are the traditional approach to storing biological samples in biobanks. These systems involve manual handling of samples, where technicians store and retrieve specimens using handheld tools such as cryotongs.

• End-User: Expansion of biobanks in pharmaceutical sector for drug development

  Academic and research institutes play a significant role in the biobanking industry due to their involvement in basic and applied research and collaboration with other organizations. These institutions require high-quality biospecimens to develop new therapies, drive precision medicine, and understand disease mechanisms. Hospitals form another crucial end-user segment in the biobanking industry as they routinely collect samples from patients for clinical studies, diagnosis, or treatment purposes. The need-based preferences of hospitals revolve around easy integration with existing infrastructure, secure storage systems to maintain patient privacy, and ensuring sample integrity during transportation between facilities. Pharmaceutical and biotechnology companies leverage biobanking for drug discovery, clinical trials, and development of advanced therapeutics. These companies demand robust storage capabilities for diverse sample types, international regulatory compliance standards, and reliable sample tracking systems to maintain the integrity of their data and biospecimens.

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Biobanking Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Biobanking Market.

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Biobanking Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

The value chain of the Biobanking Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

The pricing analysis comprehensively evaluates how a product or service is priced within the Biobanking Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Biobanking Market.

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Biobanking Market.

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Biobanking Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

The trade analysis of the Biobanking Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

The regulatory framework analysis for the Biobanking Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biobanking Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biobanking Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

• New biobanking partnership safeguards the genetic diversity of America's endangered species

  Revive & Restore, in collaboration with the U.S. Fish & Wildlife Service, ViaGen Pets & Equine, U.S. Department of Agriculture, and San Diego Zoo Wildlife Alliance, has announced a groundbreaking initiative in biobanking for U.S. endangered species. This multi-institution collaboration establishes the first systematic biobanking pipeline for U.S. threatened and endangered species, safeguarding genetic diversity for present and future recovery efforts. Biobanking entails the intentional and indefinite preservation of living cells, tissues, and gametes. [Published On: 2023-10-03]

• Crown Bioscience to Acquire Indivumed’s Service Business and Supporting Biobank

  Crown Bioscience, a global contract research organization, has signed an agreement to acquire the IndivuServ business unit of Indivumed GmbH. This transaction includes a biobank with nearly one million samples and 60 clinical divisions across the US, Europe, and Asia, providing access to a wide range of biospecimens and blood samples. 'IndivuMed Therapeutics' continues translating high-quality biospecimens into multi-omics data, while Crown Bioscience focuses on offering biomarker development services. [Published On: 2023-01-25]

• CNIO biobank receives EUR 800,000 from the EU

  The REACT Project, led by the National Serum Institute in Denmark (Statens Serum Institute, SSI), has received 7 million euros from the EU to research lower respiratory tract infections in biobanking. In addition to Denmark and Sweden, Spain and South Africa also participate in this initiative. The Spanish National Cancer Center (CNIO) and the Institute of Bioengineering of Catalonia (IBEC) receive almost 25% of the global budget. [Published On: 2022-07-05]

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biobanking Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

The report delves into recent significant developments in the Biobanking Market, highlighting leading vendors and their innovative profiles. These include Bay Biosciences LLC, Firalis Group, Greiner AG, BioKryo by L’AIR LIQUIDE S.A., SPT Labtech Ltd., CTIBiotech, Avantor, Inc., PHC Holdings Corporation, UK Biobank Limited, BioIVT LLC, ASKION GmbH, Hamilton Company, Becton, Dickinson and Company, Tecan Trading AG, Taylor-Wharton, Sopachem NV/SA, Merck KgaA, Cryoport Systems, LLC, STEMCELL Technologies Inc., Promega Corporation, Charles River Laboratories International, Inc., BocaBio, Azenta Life Sciences, AMS Biotechnology (Europe) Limited, ProteoGenex, QIAGEN N.V., Cureline, Inc., US Biolab Corporation, Inc., Thermo Fisher Scientific Inc., and Micronic Holding B.V..

This research report categorizes the Biobanking Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product
  • Consumables
  • Equipment & Instruments
  • Services
  • Software
• Sample Type
  • Biological Fluids
  • Blood Products
  • Cell Lines
  • Human Tissues
  • Nucleic Acids
• Storage Type
  • Automated
  • Manual
• Application
  • Clinical Research
  • Life Science Research
  • Regenerative Medicine
• End-User
  • Academic & Research Institutes
  • Hospitals
  • Pharmaceutical & Biotechnology

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

1. What is the current market size and projected growth?
2. Which products, segments, applications, and regions offer promising investment opportunities?
3. What are the prevailing technology trends and regulatory frameworks?
4. What is the market share and positioning of the leading vendors?
5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?